Collectively, our data suggest that altered expression of certain IRGs correlated with survival in breast cancer patients, perhaps owing to changes in expression of tumor-related TFs, and that the tumor suppressors TP63 and ELF5 can exert their anti-tumor effects by disrupting immune responses in the tumor microenvironment. Here, TP63 is linked to breast carcinoma.